NCT03212716

Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.

Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A.

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: University Hospital, Lille · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate the possibility to repropose marketed drugs as antiviral ones, based on their ability to reverse the transcriptomic signature of the infected cells. This strategy has to be considered is the context of emerging viral diseases and of increase of resistance to antivirals. Concerning infection by Influenza viruses, the main drugs were identified and evaluated on in vitro and in vivo models: diltiazem. Therefore, it will be assess the efficacy of these the drug, compared to placebo, to treat severe flu.

Conditions

• Flu

Interventions

Type	Name	Description
DRUG	Oseltamivir	150 mg twice a day during 10 days (ANSM guidelines for severe flu).
DRUG	Diltiazem	60 mgx3 per day during 10 days.
DRUG	Placebos	Placebo of diltiazem

Timeline

• Start date: 2017-12-23
• Primary completion: 2022-05-04
• Completion: 2022-05-04
• First posted: 2017-07-11
• Last updated: 2023-02-06

Locations

19 sites across 1 country: France